Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Physiomics ( (GB:PYC) ) has provided an update.
Physiomics plc has secured a new contract with an existing client to apply its PK/PD modelling and simulation expertise for a non-oncology therapeutic. The project aims to support the preclinical-to-clinical translation and inform human dosing schemes for a First in Human clinical trial. Valued at £98,600, the contract underscores Physiomics’ capability to provide integrated modelling and simulation solutions throughout the drug development lifecycle, enhancing experimental and clinical trial design and accelerating drug development programs.
Spark’s Take on GB:PYC Stock
According to Spark, TipRanks’ AI Analyst, GB:PYC is a Underperform.
Physiomics’ stock score is primarily impacted by significant financial instability, including declining revenues and negative profit margins. Technical indicators reinforce a bearish outlook. While recent corporate events suggest potential growth pathways, current valuation issues and financial challenges remain significant obstacles.
To see Spark’s full report on GB:PYC stock, click here.
More about Physiomics
Physiomics plc is a leading company in mathematical modelling, data science, and biostatistics, specializing in the development of new therapeutics and personalized medicine solutions. The company leverages its expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to assist biotech and pharma companies in optimizing their drug development processes. Physiomics has contributed to over 100 commercial projects and has worked with notable clients such as Merck KGaA, Astellas, and Bicycle Therapeutics.
Average Trading Volume: 8,482,811
Technical Sentiment Signal: Sell
Current Market Cap: £1.44M
Learn more about PYC stock on TipRanks’ Stock Analysis page.